Jaguar Health (NASDAQ:JAGX) Share Price Passes Above Fifty Day Moving Average – Here’s Why

Shares of Jaguar Health, Inc. (NASDAQ:JAGX) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.18 and traded as high as $1.19. Jaguar Health shares last traded at $1.14, with a volume of 309,156 shares traded.

Analyst Ratings Changes

Separately, StockNews.com raised Jaguar Health from a “sell” rating to a “hold” rating in a research report on Friday, September 13th.

Jaguar Health Stock Performance

The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.60 and a current ratio of 2.10. The business has a 50-day moving average price of $1.18 and a 200-day moving average price of $4.54.

Jaguar Health (NASDAQ:JAGX) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($4.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.84). Jaguar Health had a negative return on equity of 412.63% and a negative net margin of 350.18%. The firm had revenue of $2.72 million for the quarter. On average, equities analysts expect that Jaguar Health, Inc. will post -0.78 EPS for the current year.

Institutional Investors Weigh In On Jaguar Health

A hedge fund recently bought a new stake in Jaguar Health stock. Perritt Capital Management Inc acquired a new stake in shares of Jaguar Health, Inc. (NASDAQ:JAGX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned approximately 0.51% of Jaguar Health at the end of the most recent reporting period. 12.04% of the stock is owned by hedge funds and other institutional investors.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.